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Abstract
In a continuing study, we explored how the individual rings in neo-tanshinlactone (1) influence its
potent and selective in vitro anti-breast cancer activity. Accordingly, we discovered a novel class of
anti-breast cancer agents, 2-(furan-2-yl) naphthalen-1-ol derivatives, based on an active C-ring
opened model compound 5. Further optimization led to 18 and 21, which showed decreased cytotoxic
potency, but better selectivity than neo-tanshinlactone analog 2. Interestingly, compound 20 showed
broad cytotoxicity against human cancer cell lines.
Introduction
Breast cancer is the most common malignancy and the second leading cause of cancer death
in women today.1, 2 According to the American Cancer Society, breast cancer accounts for
more than one quarter of cancers diagnosed in US women. Estrogens play crucial roles in breast
cancer development and growth, and estrogen-stimulated growth in tumor cells (as well as in
normal cells) requires estrogen receptors (ERs).3 About two-thirds of human breast tumors
express higher levels of ERs than normal breast tissues.4 Much effort has been devoted to block
estrogen formation and action.2 The most widely used therapy for antagonizing ER function
is the antiestrogen tamoxifen (TAM), which binds to the ER and blocks downstream signaling
(Figure 1).
However, current breast cancer therapies like TAM achieve meaningful clinical results in only
30–40% of patients, because drug resistance usually develops after one or two years of
treatment.2 This resistance occurs via several mechanisms, including induction of estrogen-
independent pathways for breast cancer cell growth, over-expression of human epidermal
growth factor receptor 2 (HER2), and functional crosstalk between ER and HER2.5–7 A
common clinical strategy to overcome drug resistance is to combine an anti-estrogen with
another cytotoxic drug, such as anastrozole, an aromatase inhibitor.8, 9 Even so, patients still
relapse and cancer reoccurs; therefore, new drug chemotypes with new mechanisms of action
are still needed.
Neo-tanshinlactone (1) (Figure 1), a component of the Chinese traditional medicine Tanshen,
showed significant and selective cytotoxic activity as compared to TAM.10 Compound 2
(Figure 1), a congener of 1, is about twice as active as 1 against SK-BR-3 cell line.11 1 is a
tetracyclic natural product and may be more structurally complex than is necessary for optimal
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pharmacologic effects. A complex lead compound may have a simpler pharmacophoric moiety
buried within its structure, and if this pharmacophore can be clearly defined and ‘dissected
out’, the resulting biologically active, simpler molecule may have improved synthetic
tractability and be more useful as a scaffold for further analog design. To study the individual
contribution of the A-, C-, and D-rings of 1 to the selective activity against breast cancer cells,
we first prepared four novel ring-opened model compounds (4–7) (Figure 2).
The preliminary structure-activity relationship (SAR) study results showed that only
compound 5, which has an opened C-ring (cleavage of bond 2), showed in vitro anti-breast
cancer activity, although it was somewhat less potent than parent compound 3 against MCF-7
cell replication. Further structural modification of 5 generated a series of 2-(furan-2-yl)
naphthalen-1-ol derivatives (18–28), which retained potent in vitro anti-breast cancer activity
as well as high selectivity against different breast cancer cell lines, especially compound 18.
Interestingly, compound 20, a closely related structural derivative of 18, showed broad in
vitro cytotoxicity against all human cancer cell lines tested. Preliminary pharmacophore studies
and dihedral energy analyses demonstrated that 18 could adopt a conformation close to the
tetracyclic structure of 1 and 2 via intramolecular hydrogen bonding. In comparison, the
conformation of 20 was more flexible, which could account for its broader spectrum of activity.
Results and Discussion
As a first step in the current work, we investigated the individual contributions of A-, C-, and
D-rings of the neo-tanshinlactone molecule to the biological activity. Systematic structural
simplification of 3 by removal of the A-, C-, and D-rings afforded model compounds 4, 5, 6,
and 7, respectively (Figure 2). Scheme 1 shows the syntheses of these target compounds.
Intermediate 9 was obtained via a tandem alkylation/intramolecular aldol reaction with
commercially available 8.12 4 was obtained by treatment of 9 with boron tribromide at 50 °C,
followed by treatment with 2-iodopropane to remove the methyl group and incorporate an
isopropyl group. 5 was synthesized through hydrolysis of the lactone ring of 10. 11 underwent
esterification with furan-3-carbonyl chloride to provide 6. 7 was synthesized from 12 with 3-
bromoprop-1-yne.13
Compounds 4–7 were tested for in vitro anticancer activity against two human breast cancer
cell lines, MCF-7 (ER+) and SK-BR-3 (HER2+) (Table 1). Compound 4, without an A-ring
moiety, was much less potent than its tetracyclic analog 3. The activity of 5, a C-ring opened
compound, was comparable to that of 3 against MCF-7 replication (less than twofold
difference). However, compound 6, another C-ring opened compound but with cleavage of
bond-3 rather than bond-2, was inactive against the tested breast cancer cell lines. Compound
7, a D-ring opened compound, showed marginal activity against the two breast cancer cell
lines. The results demonstrated that both the A-ring and D-ring are important in maintaining
the biological activity of this compound type. The SAR results of 5 and 6 could be explained
by the postulate that intramolecular hydrogen bonding between –COOH and OH groups in 5
maintains the compound’s conformation in a more ring-like structure.
Accordingly, conformational analysis was conducted to study the molecular geometries of 4–
7, and the potential SAR relevance of solution structures. As shown in Figure 3, 4–7 possess
most of the pharmacophore (PCH) features present in the reference compound 2, including
aromatic center, hydrophobic region, hydrogen bond donor and acceptor. However, several
key features are also missing in 4–7 in comparison to 2, i.e. two aromatic centers in 4 and 7,
and a closed ring in 5 and 6. Interestingly, 5 can form one additional intramolecular hydrogen
bond between –COOH and –OH groups in the lowest energy conformer. This hydrogen bond
could ‘lock’ the structure into a conformation that is close to the tetracyclic scaffold. Thus,
intramolecular hydrogen bonding in 5 may help the compound retain biological potency.
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However, 5 was much less active compared with 2, which may be due to their differences in
susceptibility to efflux transporters or cellular uptake or different binding affinity with the
targets. Additional studies will be performed to address these possibilities.
Compound 5 was selected for further structure optimization in order to establish SAR
correlations and to identify more active derivatives with the desired biological properties.
Substituents on the 5-scaffold will affect the molecule’s overall three-dimensional structure
and, thus, the compound’s interaction with its target, which will translate into increased or
decreased anti-breast cancer activity. We designed, synthesized, and tested 11 new analogs
(Scheme 2, Table 2). Hydrolysis of 13 afforded 1414. The hydroxy group of 14 was methylated
by using 18-crown-6 as phase transfer agent, as reported by Glover et al.15 The resulting analog
15 was converted to the methyl ester 16 with thionyl chloride and methanol at room
temperature.16 Compound 17 was obtained by reduction of 13 with lithium aluminum hydride.
In order to test for a potential relationship between the intramolecular hydrogen bond (COOH-
and OH-groups) and the selective in vitro anti-breast cancer activity, a specific target sub-set
(18–20. Table 2) was designed. 18, with OH at position R4 and COOH at position R5, can form
an intramolecular hydrogen bond. However, in 19, one hydrogen donor has been effectively
removed by methylation of the OH in 18, and in 20, both hydrogen bond donors are blocked
with methyl groups. 21–28 were designed to further study SAR of various substituents on the
molecule. The newly synthesized analogs 18–28 were tested initially for in vitro anticancer
activity against two human breast cancer cell lines, MCF-7 (ER+) and SK-BR-3 cells (HER2
+) (Table 2). Both 18 and 20 showed similar activity to TAM against MCF-7 (ED50 3.3 and
2.5 µg/mL, respectively), while 18 showed fivefold better activity than TAM against SK-BR-3
(ED50 1.0 µg/mL) and 20 showed about fourfold better activity than TAM against SK-BR-3
(ED50 1.2 µg/mL). 19 displayed similar activity to TAM against both cell lines. From the
ED50 values of compounds 5, 18, and 21, the SAR study suggested that the R1 substituent
influenced the in vitro anticancer activity and hydrophobic groups were favored at this position.
At the R2 position, methyl was preferable to ethyl (18 vs 24), and at the R3 position, hydrogen
was favored over methyl (18 vs 25).
To examine human tumor-tissue-type selectivity, active compounds 18, 20, and 21 (ED50
values >4.0 µg/mL were considered not active) were selected for testing against a limited but
diverse set of human cancer cell lines, using 2 as a positive control and “gold-standard”.
Compounds 18 and 21 were active only against certain breast cancer cell lines and not active
against other tumor tissue cells tested, such as A549 lung cancer or DU145 prostate cancer cell
lines. Thus, these two compounds had high tissue selectivity. More interestingly, 18 and 21
also showed very high potency (ED50 0.3 and 0.6 µg/mL, respectively) and selectivity toward
the ZR-7-51 (ER+,HER2+) cell line. Compound 18 was three times less potent against SK-
BR-3 (HER2+) (ED50 0.9 µg/mL) and ten times less potent against MCF-7 (ER+) (ED50 3.3
µg/mL). 21 was six times less potent against SK-BR-3 (HER2+) (ED50 3.5 µg/mL) and 33
times less potent against MCF-7 (ER+) (ED50 >20 µg/mL). Meanwhile, 2 showed similar
potency against ZR-7-51 and SK-BR-3 and was only two times more potent against ZR-7-51
than MCF-7. In summary, 18 and 21 were more potent against ZR-75-1 than cell lines over-
expressing either ER or HER2 (MCF-7 or SK-BR-3), and much more potent than cell lines not
over-expressing ER or HER2 (remaining cell lines in the panel). Unexpectedly, 20 showed
activity against all cancer cell lines tested.
To further explore the physico-chemical basis for the different selectivity profiles between
18 and 20, the dihedral energy analyses were performed over 360 degrees (Figure 4). Compared
with 2, 18 retains three aromatic centers and possesses one additional intramolecular hydrogen
bond. This hydrogen bond helps to ‘lock’ the conformation close to that of 2, which may explain
why the activity pattern of 18 similar to that of 2, but with increased selectivity. The narrow
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shape of the potential energy well for the dihedral angle between the naphthalene and furan
rings implies that it is difficult to vary the angle from the minimum of −135 degree (Figure 4).
Thus, the compound’s structure is fairly rigid, leading to a small possibility for 18 to bind to
a diverse set of targets. Compound 20 also retains three aromatic centers and hydrogen bond
acceptors in common with the tetracyclic compound 2. However, the intramolecular hydrogen
bond found in 18 cannot be formed in 20. The dihedral angle between the naphthalene ring
and the furan ring is more flexible as seen in Figure 4.17 In comparison to 18, the potential
energy surface around the minimum is much flatter and there are fewer energy barriers. As a
result, the increased structural flexibility in 20 could permit multi-target interactions and
account for its observed broader activity spectrum.
Conclusions
In summary, current data have led to new developments and insights about neo-tanshinlactone-
based selective anti-breast cancer active compounds. We demonstrated that aromatic rings A
and D were important for the activity. Importantly, we discovered that ring C could be opened
through hydrolysis of the ester bond, while keeping the desired biological activity. A new class
of active C ring opened compounds, 2-(furan-2-yl) naphthalen-1-ol derivatives, was
subsequently developed. Compounds 18 and 21 exhibited much higher selectivity against
certain breast cancer cell lines than neo-tanshinlactone analog 2. In addition, compound 20 had
potent activity against all cell lines tested, suggesting a different mechanism of action from its
structural derivatives. Conformational searches and dihedral energy analyses of 18 and 20
suggested that intramolecular hydrogen bonding was important to form a rigid conformation
and improved the in vitro anticancer selectivity of 18. Refinement of the preliminary
pharmacophore and conclusion about active conformation will require target identification and
analysis of compound interaction. Mechanistic work is underway toward this goal, and results
will be reported as they are available. Overall, our current results establish a new scaffold as
a promising structure for the development of investigational anti-breast cancer agents. Novel
target compounds incorporating the important structural features identified herein are being
synthesized for testing and will be reported in due course.
Experimental Section
Materials and Methods
Melting points were measured with a Fisher Johns melting apparatus without correction.
The 1H and 13C NMR spectra were measured on a 300 MHz Varian Gemini 2000 spectrometer
using TMS as internal standard. The solvent used was CDCl3 unless indicated. Mass spectra
were measured on a Shimadzu LC-MS2010 instrument. Thin-layer chromatography (TLC)
and preparative TLC were performed on precoated silica gel GF plates purchased from Merck,
Inc. Biotage Flash+ or Isco Companion systems were used for flash chromatography. Silica
gel (200–400mesh) from Aldrich, Inc. was used for column chromatography. All other
chemicals were obtained from Aldrich, Inc, and Fisher, Inc. All final compounds are >95%
pure on the basis of two HPLC conditions.
7-Methoxy-3-methyl-4H-furo[3,2-c]chromen-4-one (9)—To a solution of 8 (199 mg,
1.04 mmol) in toluene (9 mL) was added a mixture of HOAc (0.30 mL, 5.20 mmol) and
NH4OAc (400 mg, 5.20 mmol) in EtOH (3 mL) and chloroacetone (0.42 mL, 5.20 mmol). The
mixture was refluxed 24 h. After cooling, the mixture was diluted with H2O and extracted with
EtOAc. The organic layer was dried over Na2SO4, filtered, and evaporated. The residue was
purified by column chromatography to give 9 as white solid. 65% yield; mp 148–150 °C; 1H
NMR (300 MHz, CDCl3, ppm): δ 2.34 (d, J = 1.2 Hz, 3H, CH3), 3.88 (s, 3H, OCH3), 6.88–
6.93 (m, 2H, aromatic), 7.33 (d, J = 1.5 Hz, 1H, OCH), 7.71–7.74 (m, 1H, aromatic).
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7-Isopropoxy-3-methyl-4H-furo[3,2-c]chromen-4-one (4)—To a solution of 9 (46 mg,
0.2 mmol) in DCM (3 mL) was added BBr3 (0.6 mL, 0.6 mmol) dropwise at 0 °C. The reaction
mixture was refluxed for 3 h. Water was added to quench the reaction. The solution was
extracted with CHCl3 and concentrated for the next step. The above concentrated solid was
dissolved in DMF (1 mL) and acetone (3 mL). CsCO3 (195 mg, 0.6 mmol) and 2-iodopropane
(0.06 mL, 0.6 mmol) were added to the above solution. The reaction mixture was stirred at
room temperature for 12 h. After removal of solvent, the residue was purified by column
chromatography to give 4 as a white solid. 30 % yield; mp 85–87°C; 1H NMR (300 MHz,
CDCl3, ppm): δ 1.38 (d, J = 6.0 Hz, 6H, CH(CH3)2), 2.34 (s, 3H, CH3), 4.61 (h, J = 6.0 Hz,
1H, CH), 6.86–6.90 (m, 2H, aromatic), 7.33 (s, 1H, OCH), 7.71 (d, J = 8.4 Hz, 1H, aromatic);
HRMS for ([M+H]+): calcd. 259.0965, found: 259.0961.
5-Methylnaphthalen-1-yl furan-3-carboxylate (6)—5-Methylnaphthalen-1-ol (158 mg,
1.00 mmol) was dissolved in THF (5 mL), then DMAP (5 mg) and ethyldiisopropylamine (0.18
mL, 1.02 mmol) were added, and the mixture was cooled to 0 °C for 10 min. Freshly prepared
2-bromo-4-methylbenzoyl chloride in dry THF (10 mL) was added to the mixture, and the
resulting mixture was stirred at 25 °C for 2 h and quenched by the addition of water (15 mL).
The organic layer was washed with HCl and NaHCO3 and then dried (Na2SO4) and
concentrated in vacuo. The residue was purified with flash chromatography to give 6. 46%
yield; mp 53–55°C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.72 (s, 3H, CH3), 6.97 (dd, J = 0.6,
5.2 Hz, 1H, aromatic), 7.33–7.42 (m, 3H, aromatic), 7.51–7.56 (m, 2H, aromatic), 7.79 (d, J
= 8.1 Hz, 1H, aromatic), 7.93 (d, J = 8.4 Hz,1H, aromatic), 8.32–8.33 (m, 1H, aromatic). HRMS
for ([M+H]+): calcd. 253.0859, found: 253.0869.
4-(Prop-2-ynyloxy)-2H-benzo[h]chromen-2-one (7)—To a mixture of 12 (212 mg, 1.00
mmol mmol), K2CO3 (300 mg, 2.17 mmol) in acetone (8 mL) was added 3-bromoprop-1-yne
(0.17 mL, 1.50 mmol). The mixture was refluxed 12 h. After cooling, the mixture was filtered,
concentrated, diluted with H2O and extracted with EtOAc. The organic layer was dried over
Na2SO4, filtered, and evaporated. The residue was purified by flash chromatography to give
7 as a light yellow solid. 40% yield; mp 205–207 °C; 1H NMR (300 MHz, CDCl3, ppm): δ
2.70 (t, J = 2.4 Hz, 1H, CCH), 4.92 (d, J = 2.4 Hz, 2H, OCH2), 5.93 (s, 1H, COCH), 7.62–7.71
(m, 3H, aromatic), 7.80–7.90 (m, 2H, aromatic), 8.54–8.58 (m, 1H, aromatic); HRMS for ([M
+H]+): calcd. 251.0703, found: 251.0697.
General procedure for synthesis of 5, 18, 21, 24–26—Lactone 13 (0.1 mmol) was
refluxed in ethanolic aqueous potassium hydroxide (5%, 5 mL) for 3.5 h. Then the reaction
mixture was cooled and quenched by pouring into ice, acidified with 6N HCl, and extracted
with CHCl3 (3×5 mL). Removal of solvent, drying (Na2SO4), and chromatographic
purification gave the hydrolyzed product as a solid.
2-(1-Hydroxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (5)—93% yield;
mp 194–196 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 2.27 (d, J = 1.2 Hz, 3H, CH3),
7.51–7.55 (m, 5H, aromatic & OCH), 7.86–7.89 (m, 1H, aromatic), 8.40–8.44 (m, 1H,
aromatic); 13C NMR (300 MHz, CD3COCD3, ppm): δ 10.40, 114.23, 116.83, 120.49, 122.77,
124.28, 126.32, 127.57, 128.16, 128.27, 128.28, 136.14, 141.59, 152.66, 157.87, 169.28;
HRMS for ([M-H]+): calcd. 267.0657, found: 267.0663.
2-(5-Ethyl-1-hydroxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (18)—
90% yield; mp 151–153 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 1.35 (t, J = 7.5 Hz,
3H, CH2CH3), 2.25 (d, J = 0.9 Hz, 3H, CH3), 3.08 (q, J = 7.5 Hz, 2H, CH2CH3), 7.35–7.37
(m, 2H, aromatic), 7.41 (d, J = 1.2 Hz, 1H, OCH), 7.48 (d, J = 8.7 Hz, 1H, aromatic), 7.62 (d,
J = 9.0 Hz, 1H, aromatic), 8.24–8.28 (m, 1H, aromatic); 13C NMR (300 MHz, CD3COCD3,
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ppm): δ 10.59, 15.63, 26.70, 114.97, 115.54, 120.08, 123.07, 123.51, 125.60, 126.91, 128.26,
128.85, 134.14, 140.47, 140.69, 153.94, 155.61, 171.54; HRMS for ([M-H]+): calcd. 295.0976,
found: 295.0972.
2-(1-Hydroxy-5-methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (21)
—80% yield; mp 173–175 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 2.41 (s, 3H, CH3),
4.00 (s, 3H, OCH3), 6.98 (d, J = 7.5 Hz, 1H, aromatic), 7.38 (t, J = 8.1 Hz, 1H, aromatic), 7.51
(d, J = 9.0 Hz, 1H, aromatic), 7.64 (s, 1H, OCH) 7.78 (d, J = 8.7 Hz, 1H, aromatic), 7.94 (d,
J = 8.7 Hz, 1H, aromatic). HRMS for ([M-H]+): calcd. 297.0768, found: 297.0765.
4-Ethyl-2-(5-ethyl-1-hydroxynaphthalen-2-yl)furan-3-carboxylic acid (24)—90%
yield; mp 153–155 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 1.24 (t, J = 7.5 Hz, 3H,
CH2CH3), 1.35 (t, J = 7.5 Hz, 3H, CH2CH3), 2.78 (q, J = 7.5 Hz, 2H, CH2CH3), 3.07 (q, J =
7.5 Hz, 2H, CH2CH3), 7.34–7.36 (m, 2H, aromatic), 7.39 (s, 1H, OCH), 7.49 (d, J = 9.3 Hz,
1H, aromatic), 7.60 (d, J = 9.3 Hz, 1H, aromatic), 8.24–8.27 (m, 1H, aromatic). HRMS for
([M-H]+): calcd. 309.1132, found: 309.1124.
2-(5-Ethyl-1-hydroxynaphthalen-2-yl)-4,5-dimethylfuran-3-carboxylic acid (25)
—66% yield; mp 158–160 °C; 1H NMR (300 MHz, CD3OD, ppm): δ 1.35 (t, J = 7.8 Hz, 3H,
CH2CH3), 2.17 (s, 3H, CH3), 2.26 (s, 3H, CH3), 3.07 (q, J = 7.8 Hz, 2H, CH2CH3), 7.32–7.38
(m, 2H, aromatic), 7.49 (d, J = 9.0 Hz, 1H, aromatic), 7.60 (d, J = 9.0 Hz, 1H, aromatic), 8.23–
8.26 (m, 1H, aromatic). HRMS for ([M-H]+): calcd. 309.1132, found: 309.1140.
2-(5-Ethoxy-1-hydroxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (26)—
56% yield; mp 208–210 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 1.51 (t, J = 7.8 Hz,
3H, CH2CH3), 2.33 (s, 3H, CH3), 4.23 (q, J = 6.9 Hz, 2H, CH2CH3), 6.97 (d, J = 7.8 Hz, 1H,
aromatic), 7.38 (t, J = 8.7 Hz, 1H, aromatic), 7.48 (d, J = 8.7 Hz, 1H), 7.59 (s, 1H, OCH), 7.82
(d, J = 8.7 Hz, 1H, aromatic), 7.82 (d, J = 8.7 Hz, 1H, aromatic). HRMS for ([M-H]+): calcd.
311.0919, found: 311.0940.
General procedure for synthesis of methyl ethers—Compound 13 (0.1 mmol) was
refluxed in ethanolic aqueous potassium hydroxide (5%, 5 mL) for 3.5 h. The solution was
washed with CHCl3 and evaporated to give the dipotassium salt, which was refluxed for 24 h
with 18-crown-6 (4.35 mg, 0.0145 mmol) and methyl iodide (0.01 mL, 0.159 mmol) in
acetonitrile (5 mL). The acetonitrile was removed in vacuo and after dilution with CHCl3. The
mixture was washed with water, dried, and concentrated to give an oil. The residue was purified
with flash chromatography to give the methyl ether derivative.
2-(5-Ethyl-1-methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (19)—
39% yield; mp 128–130 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.37 (t, J = 7.8 Hz, 3H,
CH2CH3), 2.46 (d, J = 1.2 Hz, 3H, CH3),3.09 (q, J = 7.8 Hz, 2H, CH2CH3), 3.73 (s, 3H,
OCH3), 7.35–7.52 (m, 4H, aromatic & OCH), 7.82 (d, J = 9.3 Hz, 1H, aromatic), 8.08 (d, J =
9.9 Hz, 1H, aromatic). HRMS for ([M-H]+): calcd. 309.1127, found: 309.1139.
2-(1-Methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylic acid (22)—46% yield;
mp 118–120 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 2.25 (d, J = 0.9 Hz, 3H, CH3), 3.74 (s,
3H, OCH3), 7.35 (d, J = 1.5 Hz, 1H, OCH), 7.47 (d, J = 8.7 Hz, 1H, aromatic), 7.51–7.54 (m,
2H, aromatic), 7.62 (d, J = 8.4 Hz, 1H, aromatic), 7.83–7.86 (m, 1H, aromatic), 8.18–8.22 (m,
1H, aromatic). HRMS for ([M-H]+): calcd. 281.0814, found: 281.0827.
General procedure for synthesis of methyl esters—Thionyl chloride (0.05 mL, 0.45
mmol) was added dropwise at 0 °C to a solution of 15 (0.14 mmol) in MeOH (15 mL). The
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solution was then stirred at room temperature for 12 h. The solvent was evaporated, and the
residue was dissolved in EtOAc and washed with a saturated aqueous solution of NaHCO3 and
brine. The organic phase was dried over Na2SO4 and evaporated under reduced pressure to
give methyl ester derivative.
Methyl 2-(5-ethyl-1-methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylate (20)
—82% yield; mp 121–123 °C; 1H NMR (300 MHz, CDCl3, ppm): δ 1.39 (t, J = 7.8 Hz, 3H,
CH2CH3), 2.52 (s, 3H, CH3), 3.11 (q, J = 7.5 Hz, 1H, CH2CH3), 3.68 (s, 3H, OCH3), 3.69 (s,
3H, COOCH3), 7.34–7.49 (m, 3H, aromatic & OCH), 7.54 (d, J = 8.7 Hz, 1H, aromatic), 7.85
(d, J = 8.7 Hz, 1H, aromatic), 8.10 (d, J = 8.4 Hz, 1H, aromatic); 13C NMR (300 MHz,
CD3COCD3, ppm): δ 10.02, 15.95, 27.00, 51.77, 62.77, 117.86, 120.08, 120.42, 122.15,
123.08, 127.46, 127.58, 128.31, 129.72, 134.87, 141.41, 141.87, 155.77, 156.62, 165.47;
HRMS for ([M+H]+): calcd. 325.1434, found: 325.1430.
Methyl 2-(1-methoxynaphthalen-2-yl)-4-methylfuran-3-carboxylate (23)—32%
yield; 1H NMR (300 MHz, CDCl3, ppm): δ 2.25 (d, J = 1.2 Hz, 3H, CH3), 3.69 (s, 3H,
OCH3), 3.71 (s, 3H, COOCH3), 7.35 (d, J = 1.5 Hz, 1H, OCH), 7.50–7.57 (m, 3H, aromatic),
7.64 (d, J = 8.4 Hz, 1H, d, J = 1.5 Hz, 1H, OCH), 7.84–7.88 (m, 1H, aromatic), 8.19–8.23 (m,
1H, aromatic). HRMS for ([M+H]+): calcd. 297.1121, found: 297.1110.
General procedure for synthesis of 27 and 28—LiAlH4 (60 mg, 16 mmol) was added
at 0 °C to a solution of 13 (0.1 mmol) in THF (5 mL). The solution was then refluxed for 5 h.
Then the reaction mixture was cooled and quenched by pouring into ice, acidified with 2N
HCl, and extracted with diethyl ether: DCM=2:1. The solvent was evaporated after drying.
The residue was purified by flash chromatography to give the product.
5-Ethyl-2-(3-(hydroxymethyl)-4-methylfuran-2-yl)naphthalen-1-ol (27)—95%
yield; 1H NMR (300 MHz, CDCl3, ppm): δ 1.38 (t, J = 7.5 Hz, 3H, CH2CH3), 2.14 (s, 3H,
CH3), 3.08 (q, J = 7.8 Hz, 2H, CH2CH3), 4.64 (s, 2H, CH2OH), 7.35–7.44 (m, 3H, aromatic),
7.54 (d, J = 8.7 Hz, 1H, aromatic), 7.64 (d, J = 9.3 Hz, 1H, aromatic), 7.99 (br, 1H, OH), 8.25
(d, J = 8.1 Hz, 1H, aromatic). HRMS for ([M-H]+): calcd. 281.1183, found: 281.1197.
2-(3-(Hydroxymethyl)-4-methylfuran-2-yl)naphthalen-1-ol (28)—87% yield; mp 95–
97 °C; 1H NMR (300 MHz, CD3COCD3, ppm): δ 2.13 (s, 3H, CH3), 4.58 (s, 2H, CH2OH),
7.45–7.56 (m, 5H, aromatic & OCH), 7.83–7.87 (m, 1H, aromatic), 8.33–8.36 (m, 1H,
aromatic); HRMS for ([M-H]+): calcd. 253.0870, found: 253.0863.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Abbreviations
ER, estrogen receptor




PM3, Parameterized Model number 3
MOE, Molecular Operating Environment
CSD, Cambridge Structural Database
DIEA, diisopropylethylamine
DMAP, 4-(dimethylamino)pyridine
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Structures of tamoxifen, neo-tanshinlactone (1) and a first generation optimized analog (2).
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Design of ring-opening model compounds (4–7).
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Pharmacophore analysis of 44–7 with reference to 2 using the PCH annotation scheme. (Purple:
H-bond donor; Blue: H-bond acceptor; Light green: Aromatic ring center; Deep green:
Hydrophobic region.) The structures of the global energy minima are shown by stick models.
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Dihedral energy analyses of 18 (top panel) and 20 (bottom panel) between the naphthalene
ring and the furan ring. The structure of the global energy minimum is shown by a ball and
stick model.
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Reagents and conditions: (a) HOAc, AcNH4, chloroacetone, toluene, EtOH, 95 °C, 65%; (b)
(i) BBr3, DCM, 50°C; (ii) 2-iodopropane, CsCO3, DMF, 50°C, 30%; (c) 5% NaOH(aq), reflux,
93%; (d) furan-3-carbonyl chloride, DIEA, DMAP, DMF, 46%; (e) 3-bromoprop-1-yne,
K2CO3, acetone, 40%.
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Reagents and conditions: (a) 5% NaOH (aq), reflux; (b) 18-crown-6, MeI, CH3CN, 90 °C; (c)
SOCl2, MeOH, rt; (d) LiAlH4, THF.
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Table 1
In vitro Anticancer Activity of 2–7 against Breast Cancer Cell Lines







mean ED50 (µg/mL), Standard error of independent determinations was less than 5%.
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